RiverWalk Therapeutics
RiverWalk Therapeutics is a preclinical drug development company developing novel adenosine A2B receptor antagonists for efficacy in certain metastatic cancers. Our technology has been proven in multiple mouse models of Triple Negative Breast Cancer and has the potential to effective in several other cancers as well. RiverWalk’s lead small molecules have demonstrated potencies to inhibit primary and metastatic tumors, stimulate the anti-cancer immune response, drastically reduce circulating tumor cells, and improve overall survival.
Founder Dr. Jean Jiang is the Zachry Distinguished University Professor in Cancer Research at UT San Antonio, Fellow of American Association for Advancement of Science (AAAS), Fellow of National Academy of Inventors (NAI), and winner of the Cancer Therapeutic Research Center Discovery of the Year Award.
** Currently fundraising **
RiverWalk on the Move
-
RiverWalk was selected as part of MassBioDrive Spring 2023 cohort. MassBioDrive is an accelerator designed to advance breakthrough science while providing opportunities to innovators from all parts of the life sciences ecosystem.
-
RiverWalk Therapeutics finished First Place with Distinction in the 2022 AIM-HI Women’s Venture Competition.
-
RiverWalk was selected to the TMCinnovation Accelerator for Cancer Therapeutics 2022 Cohort. Accelerator participants benefit from 9 months of clinical and business development education.
